MX2023009620A - Metodos terapeuticos. - Google Patents

Metodos terapeuticos.

Info

Publication number
MX2023009620A
MX2023009620A MX2023009620A MX2023009620A MX2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A
Authority
MX
Mexico
Prior art keywords
therapeutic methods
present disclosure
inclusive
administering
dose
Prior art date
Application number
MX2023009620A
Other languages
English (en)
Spanish (es)
Inventor
Barry S Coller
C Michael Gibson
Hof Arnoud W J Van''t
Original Assignee
Celecor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celecor Therapeutics Inc filed Critical Celecor Therapeutics Inc
Publication of MX2023009620A publication Critical patent/MX2023009620A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023009620A 2021-02-17 2022-02-16 Metodos terapeuticos. MX2023009620A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163150301P 2021-02-17 2021-02-17
PCT/US2022/016571 WO2022177968A1 (en) 2021-02-17 2022-02-16 Therapeutic methods

Publications (1)

Publication Number Publication Date
MX2023009620A true MX2023009620A (es) 2023-11-01

Family

ID=82931154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009620A MX2023009620A (es) 2021-02-17 2022-02-16 Metodos terapeuticos.

Country Status (10)

Country Link
US (1) US20250268902A1 (https=)
EP (1) EP4294402A4 (https=)
JP (1) JP2024507294A (https=)
KR (1) KR20230157354A (https=)
CN (1) CN117098538A (https=)
AU (1) AU2022224562A1 (https=)
BR (1) BR112023016459A2 (https=)
CA (1) CA3211215A1 (https=)
MX (1) MX2023009620A (https=)
WO (1) WO2022177968A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019771A1 (en) * 2024-07-15 2026-01-22 Celecor Therapeutics, Inc. Zalunfiban for use in the treatment of thrombotic disorder in patients with renal impairment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2804610B1 (en) * 2012-01-16 2018-10-31 The Rockefeller University Organic compounds
US11684622B2 (en) * 2018-06-19 2023-06-27 Celecor Therapeutics, Inc. Deuterated RUC-4

Also Published As

Publication number Publication date
WO2022177968A1 (en) 2022-08-25
EP4294402A4 (en) 2025-01-15
WO2022177968A9 (en) 2022-10-20
EP4294402A1 (en) 2023-12-27
JP2024507294A (ja) 2024-02-16
CA3211215A1 (en) 2022-08-25
CN117098538A (zh) 2023-11-21
BR112023016459A2 (pt) 2023-10-10
KR20230157354A (ko) 2023-11-16
AU2022224562A1 (en) 2023-08-31
WO2022177968A8 (en) 2022-11-17
US20250268902A1 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
MX2023000798A (es) Peptidos funcionalizados como agentes antivirales.
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
PH12023550160A1 (en) Combinations for the Treatment of Cancer
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
MX2025005792A (es) Combinaciones farmaceuticas y usos de las mismas
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2022009967A (es) Compuestos para el tratamiento de la infeccion por coronavirus.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2023011203A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
PH12023550780A1 (en) Line-1 inhibitors to treat disease
MX2022003845A (es) Tratamientos cognitivos medicinales.
TW200639159A (en) Treatment of pain
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2023009620A (es) Metodos terapeuticos.
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.